Company Profile

Company Overview

Singletto was founded to translate frontline clinical research into a new class of materials-applied antimicrobial technology.

Early in the COVID-19 pandemic, Singletto co-founder James (Jim) Chen, MD, a neurosurgeon with decades of experience applying photodynamic approaches across multiple medical disciplines, developed a hypothesis that these principles could be applied to face masks and other protective materials. The hypothesis emerged from a clinical reality: materials worn for extended periods in real-world settings can accumulate microbial exposure during use, yet are typically designed only as passive barriers.

Together with Singletto co-founder Thomas (Tom) Lendvay, MD, a pediatric surgeon, this hypothesis was advanced through global research efforts organized with the support of the World Health Organization. These studies focused on clinically relevant, mask-based assays designed to examine pathogen inactivation under real-world conditions.